Comprehensive genomic analysis of circulating tumor DNA for patients with advanced non-small cell lung cancer

he advent of therapies targeted to specific gene driver alterations has necessitated the development of predictive biomarkers of response that can be interrogated prior to the start of treatment. In patients with advanced non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network (NCCN) Guidelines recommend broad molecular profiling of molecular alterations, including alterations in driver genes (EGFR, ALK, ROS1, BRAF, MET, ERBB2, and RET) for which effective drugs are available, as well as KRAS, which may identify patients not likely to benefit from them (1).